IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.231
EU - Europa 5.951
AS - Asia 5.844
SA - Sud America 778
Continente sconosciuto - Info sul continente non disponibili 413
AF - Africa 84
OC - Oceania 4
Totale 22.305
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.053
SG - Singapore 2.461
CN - Cina 1.561
UA - Ucraina 973
IE - Irlanda 851
GB - Regno Unito 766
RU - Federazione Russa 692
SE - Svezia 639
BR - Brasile 634
TR - Turchia 607
FR - Francia 596
IT - Italia 592
VN - Vietnam 483
DE - Germania 370
IN - India 285
FI - Finlandia 220
CA - Canada 89
BD - Bangladesh 88
HK - Hong Kong 68
PL - Polonia 53
MX - Messico 47
AR - Argentina 45
BE - Belgio 44
IQ - Iraq 43
JP - Giappone 43
KR - Corea 33
ZA - Sudafrica 32
ES - Italia 30
NL - Olanda 30
CZ - Repubblica Ceca 22
EC - Ecuador 22
UZ - Uzbekistan 21
AT - Austria 19
CO - Colombia 19
ID - Indonesia 19
PK - Pakistan 19
VE - Venezuela 17
LT - Lituania 13
SA - Arabia Saudita 13
IR - Iran 12
JM - Giamaica 12
EG - Egitto 11
EU - Europa 11
PH - Filippine 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
IL - Israele 10
PE - Perù 10
MA - Marocco 9
PY - Paraguay 9
UY - Uruguay 9
CH - Svizzera 8
JO - Giordania 8
KE - Kenya 8
AL - Albania 7
TN - Tunisia 7
AZ - Azerbaigian 6
CR - Costa Rica 6
MY - Malesia 6
GR - Grecia 5
NP - Nepal 5
DO - Repubblica Dominicana 4
LB - Libano 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AO - Angola 3
AU - Australia 3
DZ - Algeria 3
ET - Etiopia 3
HN - Honduras 3
HU - Ungheria 3
KG - Kirghizistan 3
NI - Nicaragua 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
TW - Taiwan 3
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
GE - Georgia 2
KH - Cambogia 2
NG - Nigeria 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BM - Bermuda 1
CU - Cuba 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
Totale 21.893
Salva come PNG Salva come JPEG
Città #
Singapore 1.820
Jacksonville 1.062
Chandler 1.053
San Jose 1.038
Dublin 844
Southend 558
Ashburn 486
Dallas 413
Princeton 385
Council Bluffs 368
Beijing 353
Izmir 329
Nanjing 307
Santa Clara 246
Los Angeles 236
The Dalles 189
Cambridge 178
Wilmington 178
Ho Chi Minh City 151
Tongling 140
Boardman 134
New York 129
Ann Arbor 127
Buffalo 115
Nanchang 111
Dearborn 105
Hanoi 103
Altamura 91
Moscow 87
Chieti 67
Munich 62
São Paulo 62
Woodbridge 62
Hong Kong 58
Hebei 53
Shenyang 50
Orem 46
Tianjin 46
Brussels 43
Pescara 43
Kunming 42
Houston 39
Phoenix 39
Tokyo 38
Redondo Beach 37
Brooklyn 35
Columbus 35
Chennai 33
Denver 32
Stockholm 32
Montreal 31
Chicago 30
Seoul 30
Warsaw 30
Atlanta 29
Boston 29
Jiaxing 29
London 29
Norwalk 27
Dong Ket 24
Poplar 24
Rome 24
Hangzhou 23
Hefei 23
Johannesburg 23
Nuremberg 23
Changsha 22
Helsinki 21
Manchester 20
Tashkent 20
Da Nang 19
Falls Church 19
Frankfurt am Main 19
Kocaeli 19
Grevenbroich 18
Turku 18
Brno 17
Montesilvano 17
San Francisco 17
St Louis 17
Washington 17
Baghdad 16
Collecorvino 16
Haiphong 16
Mexico City 16
Milan 16
Hyderabad 15
Rio de Janeiro 15
San Mateo 15
Amsterdam 14
Belo Horizonte 14
Jinan 14
Kraków 14
Lanzhou 14
Orange 14
Augusta 13
Leawood 13
Mumbai 13
Toronto 12
Ankara 11
Totale 13.269
Salva come PNG Salva come JPEG
Nome #
90K (Mac-2 BP) in human milk 244
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 213
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 189
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 186
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 184
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 181
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 175
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 173
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 173
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 173
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 171
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 170
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 165
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 164
ERBB3 BINDING ANTIBODY 163
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 163
Prognostic relevance of LGALS3BP in human colorectal carcinoma 160
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 159
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 157
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 156
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 154
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 154
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 154
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 153
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 151
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 150
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 149
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 149
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 148
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 148
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 148
New Targets for Therapy in Pancreatic Cancer 146
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 145
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 144
Novel inhibitors of pvhl-elongin c binding 139
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 138
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 137
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 137
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 136
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 135
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 134
A Stochastic Model for the HIV/AIDS Dynamic Evolution 134
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 133
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 132
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 132
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 132
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 131
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 131
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 129
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 129
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 128
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 128
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 128
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth 125
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 125
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 124
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 124
Surgical treatment of adrenal metastases from non small cell lung cancer 123
[Hairy cell leukemia: prognosis and treatment] 123
DNA ploidy and S-phase fraction in pulmonary carcinoids. 123
Tumor-derived microvesicles: The metastasomes. 123
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 123
Prognostic value of 90K protein in HIV infection 122
Increased levels of soluble P-selectin in hypercholesterolemic patients 122
Tyrosine kinase inhibitors 122
Unknown primary tumors 121
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 121
Prognostic value of a novel circulating serum 90K antigen in breast cancer 120
Role of 90K protein in asthma and TH2-type cytokine expression. 120
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 119
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 118
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 118
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 117
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 117
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 116
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 116
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 116
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 116
Prognostic value of gender and primary tumor location in metastatic colon cancer 116
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 115
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 115
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 114
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 114
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 113
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 113
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 113
Combined therapy in pancreatic cancer 112
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 112
Combinations of biological response modifiers: rationale and clinical responses. 112
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 111
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 111
Phospholipase Cgamma1 is required for metastasis development and progression 111
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 111
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 110
Oral etoposide and platinum derivates in the treatment of metastatic Merkel cell carcinoma: report of three cases 110
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. 110
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 109
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies 108
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 107
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 106
Totale 13.602
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.076
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.076
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022716 0 0 5 137 90 16 15 52 65 14 93 229
2022/20232.806 210 288 173 356 315 597 159 220 329 25 73 61
2023/20241.213 109 37 99 58 67 356 261 39 14 23 16 134
2024/20253.627 200 751 610 90 64 97 124 189 320 186 402 594
2025/20266.685 553 358 707 796 572 491 1.119 374 672 619 324 100
2026/2027612 102 371 139 0 0 0 0 0 0 0 0 0
Totale 22.305